Elicio Therapeutics (ELTX) Equity Average (2020 - 2026)

Elicio Therapeutics has reported Equity Average for 7 years, with the latest figure at $99500.0 in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 108.26% year-over-year to $99500.0; the trailing twelve-month figure through Mar 2026 stood at $99500.0 (up 108.26% YoY), and the FY2025 full-year result was -$4.8 million, down 15962.3% from the prior year.
• Equity Average for Q1 2026 stood at $99500.0, down from $2.7 million in the prior quarter.
• The five-year high for Equity Average was $18.4 million in Q3 2023, with the low at -$106.0 million in Q1 2023.
• Historically, Equity Average has averaged -$28.1 million across 5 years, with a median of -$1.2 million in 2025.
• Annual changes were most pronounced in 2022 — Equity Average slumped 7922.07% — and 2025, when it surged 233.69%.
• Elicio Therapeutics' Equity Average stood at -$98.9 million in 2022, then surged by 112.46% to $12.3 million in 2023, then plunged by 222.87% to -$15.1 million in 2024, then surged by 117.99% to $2.7 million in 2025, then slumped by 96.35% to $99500.0 in 2026.
• The last three Equity Average figures came in at $99500.0 (Q1 2026), $2.7 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.